Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.
Investor's Business Daily on MSN1d
Sarepta Dives On 'Another Unfortunate Development' For Its Gene TherapySarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...
The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...
Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...
President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...
Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...
The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback